Vaccine Quality And Efficacy Articles & Analysis
19 news found
In an epidemic, better knowledge can lead to wiser policy and can save lives. Can wastewater-based measurements of SARS-CoV-2 activity help us understand the effects of COVID-19 vaccination, and how those effects might change with new variants like Delta? To understand how wastewater can help us better understand the role of vaccines during this Delta wave, we should first look back to how we ...
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics is proud to announce the launch of its innovative Influenza A Virus Mouse Models to assess the impact of virus-host interactions. These mouse models can facilitate comprehensive research into the pathogenesis, immune response, and efficacy of antiviral treatments against influenza A infections. ...
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics is proud to announce the launch of its comprehensive portfolio of ELISA Based Assays for vaccine development and bioprocess applications. Vaccine development involves a variety of assays to support vaccine research and development, from early ...
By prioritizing optimization, Alfa Chemistry ensures that their mRNA vaccine solutions remain at the forefront of the industry, consistently delivering vaccines that redefine the boundaries of vaccine technology. mRNA Vaccine Quality Control Equally crucial to the success of mRNA vaccine ...
Orginally published by https://www.globenewswire.com/ Emergent BioSolutions Inc. (NYSE:EBS) announced today a research award by the U.S. Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP) to evaluate efficacy of the company’s single-dose chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate. Emergent will begin the planning phase, the first ...
Creative Diagnostics, a global leader in offering raw materials, antibodies, and reagents for the bio-technology industry, announced the launch of Monkeypox Virus Antigens and Antibodies to support scientists focused on the research of monkeypox virus. These products are only intended for research use, not for diagnostic or clinical purposes. Monkeypox is a rare disease caused by infection with ...
The Coalition for Epidemic Preparedness Innovations (CEPI) and Vaxxinity, Inc. (Nasdaq: VAXX), a US company pioneering the development of a new class of immunotherapeutic vaccines, today announced that they will co-fund the ongoing global pivotal Phase 3 clinical trial of Vaxxinity’s next generation UB-612 COVID-19 vaccine candidate as a heterologous – or ‘mix-and-match’ ...
ByVaxxinit
Participants receiving a booster dose six months after second dose of COVAXIN™ saw significant increase (>10-fold across Alpha, Beta, Delta and Delta Plus variants) in neutralizing titers compared to baseline at six months Persistence of memory B and T cell immune responses at six months post second dose Pronounced SARS-CoV-2-specific T cell response to COVAXIN™ before and ...
BUFFALO, N.Y. — POP Biotechnologies Inc. (POP BIO) received a $599,981, two-year Phase I Small Business Innovation Research (SBIR) under Award No. 1R43AI165089-01, supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to pursue development of a potentially life-saving vaccine technology to address the ongoing ...
YourBio Health, formerly Seventh Sense Biosystems, Inc., developers of the world’s first push-button blood collection device, announced the launch of its website where UK consumers can order a convenient, easy to use, nearly painless and accurate COVID-19 antibody test. “We’re happy to launch our COVID-19 antibody test service to UK consumers today,” said Stephen Hahn, ...
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the pre-print publication of data from a Phase 2b clinical trial in children demonstrating 77 percent efficacy for a malaria vaccine candidate, R21, created by the University of Oxford that includes Novavax' Matrix-M™ adjuvant and is licensed to Serum ...
ByNovavax
EnGen Bio is an early stage biotechnology company developing a new approach to preventing and treating all Type A influenza strains—including all flu pandemics. Seasonal flu causes 50,000–250,000 deaths worldwide annually, causing the World Health Organization to declare the development of a universal flu vaccine as an urgent need in its Global Influenza Strategy (2019–2030) ...
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced final efficacy of 96.4% against mild, moderate and severe disease caused by the original COVID-19 strain in a pivotal Phase 3 trial in the United Kingdom (U.K.) of NVX–CoV2373, the company's vaccine candidate. The company also announced the complete ...
ByNovavax
EnGen Bio is an early stage biotechnology company pioneering a new approach to preventing and treating influenza, with the goal of an effective, easy-to-manufacture, shelf-stable universal flu vaccine that should confer long-term immunity to all Type A influenza strains—including all flu pandemics. Seasonal flu causes 50,000–250,000 deaths worldwide annually, causing the World Health ...
AKCP Coronavirus Vaccine Delivery Monitoring Solution The COVID-19 vaccines coming from Pfizer and Moderna both require storage and transportation at low temperatures. The Pfizer vaccine at -70°C +/- 10°C whereas Moderna requires -20°C. Both can be transferred to standard medical refrigerators for short periods of time. The latest COVID-19 vaccine to be announced from AstraZeneca ...
ByAKCP
Imaxio, a biotech company specializing in immunology announces today the sale of Trolovol® (D-penicillamine), a drug for human usage indicated for an orphan disease affecting around 1,200 patients in France. The transaction was facilitated by CMC Consulting Group. This sale is aligned with Imaxio’s willingness to refocus its business on vaccines. This is the result of several years of ...
Imaxio, a biotech company specialized in immunology, announces today having received from the USPTO (United States Patent and Trademark Office) notices of allowance for two of its latest patent applications. Submitted in 2012 and 2013, and respectively entitled “Modified coiled-coil type proteins having improved properties” and “Influenza nucleoprotein vaccines”, these ...
The aim of the OPTIVAC project is to improve the efficacy of vaccines for seasonal influenza and current pandemics. To achieve this, it will develop a candidate vaccine comprising a recombinant, proprietary, and highly immunogenic version of the influenza virus nucleoprotein (NP). The candidate vaccine from the OPTIVAC project ...
DATELINE -- During the vaccine production process, dissolved and gaseous oxygen measurement is critical to optimize the gas intertization phase. To help pharmaceutical manufacturers meet this need, METTLER TOLEDO offers a solution that combines its InPro6800 dissolved/gaseous oxygen sensors with its M300 two-channel multi-parameter transmitter. This system measures gaseous and dissolved oxygen ...